Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism

Porntipa Korprasertthaworn, Thomas M. Polasek, Michael J. Sorich, Andrew J. McLachlan, John O. Miners, Geoffrey T. Tucker and Andrew Rowland
Drug Metabolism and Disposition November 2015, 43 (11) 1806-1814; DOI: https://doi.org/10.1124/dmd.115.064790
Porntipa Korprasertthaworn
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas M. Polasek
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Sorich
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. McLachlan
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John O. Miners
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey T. Tucker
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Rowland
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, Australia (P.K., T.M.P., M.J.S., J.O.M., A.R.); Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand (P.K.); Faculty of Pharmacy, University of Sydney, Sydney, Australia (A.J.M.); and University of Sheffield (Emeritus), Sheffield, United Kingdom (G.T.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Olanzapine (OLZ) is an atypical antipsychotic used in the treatment of schizophrenia and related psychoses. The metabolism of OLZ is complex and incompletely characterized. This study aimed to elucidate the enzymes and pathways involved in the metabolism of OLZ and to determine the kinetics of OLZ oxidation and glucuronidation by human liver microsomes, recombinant cytochrome P450 (rP450) enzymes, and recombinant UDP-glucuronosyltransferase (rUGT) enzymes. An ultra-performance liquid chromatography–mass spectrometry method was developed and validated to quantify OLZ, its four oxidative metabolites (N-desmethyl-OLZ, 2-hydroxymethyl-OLZ, 7-hydroxy-OLZ, and OLZ-N-oxide), and two N-glucuronides (OLZ-10-N-glucuronide and OLZ-4′-N-glucuronide). Consistent with previous reports, UGT1A4, CYP1A2, and flavin-containing monooxygenase 3 play major roles in catalyzing the formation of OLZ-10-N-glucuronide, 7-hydroxy-OLZ, and OLZ-N-oxide, respectively. In addition, a previously uncharacterized major contribution of CYP2C8 to OLZ-N-demethylation was demonstrated. The kinetics of OLZ metabolite formation (Km and Vmax) by human liver microsomes, rP450 enzymes, and rUGT enzymes were characterized in the presence of bovine serum albumin [2% (w/v)]. Consistent with the known effect of bovine serum albumin on CYP1A2, CYP2C8, and UGT1A4 activities, Km values reported here are lower than previously reported values for OLZ metabolic pathways. In addition to CYP1A2-mediated OLZ-N-demethylation, these results suggest that other P450 enzymes, particularly CYP2C8, contribute significantly to oxidative OLZ metabolism through catalysis of OLZ-N-demethylation.

Footnotes

    • Received April 29, 2015.
    • Accepted August 31, 2015.
  • This research was supported by Simcyp Limited (a Certera company) [Simcyp Grant and Partnership Scheme].

  • dx.doi.org/10.1124/dmd.115.064790.

  • Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (11)
Drug Metabolism and Disposition
Vol. 43, Issue 11
1 Nov 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Vitro Characterization of Olanzapine Metabolism

Porntipa Korprasertthaworn, Thomas M. Polasek, Michael J. Sorich, Andrew J. McLachlan, John O. Miners, Geoffrey T. Tucker and Andrew Rowland
Drug Metabolism and Disposition November 1, 2015, 43 (11) 1806-1814; DOI: https://doi.org/10.1124/dmd.115.064790

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

In Vitro Characterization of Olanzapine Metabolism

Porntipa Korprasertthaworn, Thomas M. Polasek, Michael J. Sorich, Andrew J. McLachlan, John O. Miners, Geoffrey T. Tucker and Andrew Rowland
Drug Metabolism and Disposition November 1, 2015, 43 (11) 1806-1814; DOI: https://doi.org/10.1124/dmd.115.064790
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cytochrome P450 4F11 in lung cancer
  • SLC49A4-mediated pyrilamine transport
  • Functional Characterization of 29 CYP4F2 Variants
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics